# Nuclide record cd20 (target). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/targets/cd20/>
  a schema:BioChemEntity ;
  nuclide:kind "target" ;
  schema:identifier "cd20" ;
  schema:name "CD20"@en ;
  schema:description "CD20 is a B-cell marker; rituximab against it was the first antibody approved for cancer, in 1997."@en ;
  schema:url <https://nuclide.cc/targets/cd20/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/CD20>, <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7315>, <https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000156738>, <https://www.uniprot.org/uniprotkb/P11836/entry>, <https://www.ncbi.nlm.nih.gov/gene/931> ;
  owl:sameAs <http://www.wikidata.org/entity/Q5009796> ;
  schema:citation <https://en.wikipedia.org/wiki/CD20> ;
  nuclide:tag "antibody-target" ;
  schema:alternateName "MS4A1" ;
  nuclide:targetClass "surface-antigen" ;
  nuclide:indications <https://nuclide.cc/indications/dlbcl/> ;
  nuclide:drugs <https://nuclide.cc/drugs/ibritumomab-tiuxetan/> .